hCG vs Kisspeptin-10

hCG mimics LH directly at the testes and ovaries; kisspeptin acts at the top of the axis to stimulate the body’s own GnRH. Kisspeptin has been studied as an alternative oocyte-maturation trigger in IVF.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

hCG

A placental glycoprotein hormone that mimics luteinising hormone (LH), stimulating testicular testosterone production — a prescription fertility medicine.

BEST STUDIED FOR

Reproductive axis

Read the cited profile →

🧪

Kisspeptin-10

The shortest active fragment of kisspeptin, the hypothalamic peptide that triggers GnRH release and sits at the top of the reproductive axis.

BEST STUDIED FOR

Reproductive axis

Read the cited profile →

SIDE BY SIDE

	hCG	Kisspeptin-10
The key difference	Acts on the gonads (LH receptor)	Acts on the hypothalamus (GnRH)
Class	Reproductive axis	Reproductive axis
Mechanism	hCG binds the LH/hCG receptor on Leydig cells, stimulating testosterone and supporting spermatogenesis.	Kisspeptin binds its receptor (KISS1R/GPR54) on GnRH neurons, driving GnRH pulses and therefore LH, FSH and testosterone/oestrogen.
Status	Registered prescription medicine (fertility). Androgen-related use is regulated; in sport it is prohibited for men.	Human research tool in reproductive endocrinology (fertility, hypothalamic amenorrhoea); not an approved medicine.
Reported safety signals	Clinical series report it as generally well tolerated; oestradiol rises and gynaecomastia are described in the androgen literature.	Short-term human studies are physiological; repeated exposure can desensitise the axis in some protocols. A 2024 study also found KISS1R signalling in osteoclasts.
A key study	Reported that hCG alongside testosterone therapy preserved spermatogenesis in men. (J Urol 2013, PMID 23260550)	Reviews kisspeptin as the critical central regulator of GnRH release. (Front Endocrinol (Lausanne) 2022, PMID 35837314)

WHEN TO RESEARCH WHICH

hCG for direct gonadal stimulation; kisspeptin for physiological upstream stimulation. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[hCG] Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy — J Urol 2013. PMID 23260550
[hCG] Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility — Expert Rev Endocrinol Metab 2021. PMID 33345656
[hCG] Optimal restoration of spermatogenesis after testosterone therapy using human chorionic gonadotropin and follicle-stimulating hormone — Fertil Steril 2025. PMID 39442683
[Kisspeptin-10] The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction — Front Endocrinol (Lausanne) 2022. PMID 35837314
[Kisspeptin-10] Metabolic regulation of kisspeptin - the link between energy balance and reproduction — Nat Rev Endocrinol 2020. PMID 32427949
[Kisspeptin-10] Kisspeptin and neurokinin B: roles in reproductive health — Physiol Rev 2025. PMID 39813600

FREQUENTLY ASKED

What is the difference between hCG and Kisspeptin-10?

What is the regulatory status of hCG and Kisspeptin-10?

hCG: Registered prescription medicine (fertility). Androgen-related use is regulated; in sport it is prohibited for men. Kisspeptin-10: Human research tool in reproductive endocrinology (fertility, hypothalamic amenorrhoea); not an approved medicine.

What safety signals have been reported?

hCG: Clinical series report it as generally well tolerated; oestradiol rises and gynaecomastia are described in the androgen literature. Kisspeptin-10: Short-term human studies are physiological; repeated exposure can desensitise the axis in some protocols. A 2024 study also found KISS1R signalling in osteoclasts.

Which studies is this comparison based on?

For hCG: “Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy” (PMID 23260550); “Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility” (PMID 33345656); “Optimal restoration of spermatogenesis after testosterone therapy using human chorionic gonadotropin and follicle-stimulating hormone” (PMID 39442683). For Kisspeptin-10: “The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction” (PMID 35837314); “Metabolic regulation of kisspeptin - the link between energy balance and reproduction” (PMID 32427949); “Kisspeptin and neurokinin B: roles in reproductive health” (PMID 39813600).